https://genesisinnovations.tech/arch-closes-3b-plus-fund-as-biotech-investment-environment-shows-more-signs-of-a-revival-2/2025-03-20T09:53:47+00:00https://genesisinnovations.tech/bob-nelsen-on-arch-led-megarounds-we-want-the-ipo-book-in-the-seed-round-2/2025-03-20T10:08:58+00:00https://genesisinnovations.tech/hibercell-announces-first-patient-dosed-in-clinical-collaboration-with-merck-evaluating-hc-77366-in-combination-with-welireg-belzutifan-in-patients-with-advanced-ccrcc/2025-03-20T10:07:51+00:00https://genesisinnovations.tech/chinese-drug-maker-akeso-hailed-as-biotechs-deepseek-moment-amid-us-competition/2025-03-20T09:56:07+00:00https://genesisinnovations.tech/what-is-a-good-biomarker/2025-03-20T09:56:37+00:00https://genesisinnovations.tech/why-private-equity-healthcare-dealmaking-is-expected-to-rise-in-2025/2025-03-20T08:05:16+00:00https://genesisinnovations.tech/biotechs-top-money-raisers-of-2024/2025-03-20T09:57:51+00:00https://genesisinnovations.tech/trumps-america-first-investment-policy-raises-uncertainty-for-us-china-biotech-dealmaking/2025-03-20T09:58:24+00:00https://genesisinnovations.tech/vertex-axes-verve-gene-editing-pact-amid-shift-in-rsd-priorities/2025-03-20T09:59:01+00:00https://genesisinnovations.tech/this-anti-aging-technique-makes-human-skin-cells-act-30-years-younger-scientists-claim/2025-03-20T09:59:25+00:00https://genesisinnovations.tech/translational-omics-the-role-of-biomarkers-and-mass-spectrometry/2025-03-20T09:37:08+00:00https://genesisinnovations.tech/arch-backed-hc-bioscience-closes-doors-after-seeing-early-data-for-trana-asset/2025-03-20T09:48:03+00:00https://genesisinnovations.tech/arbor-biotechnologies-announces-73-9-million-series-c-financing-to-advance-novel-gene-editing-therapeutics/2025-03-20T09:52:00+00:00